Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices 10067 

comment until March 25, 2011. This 

process is conducted in accordance with 

5 CFR 1320.10. To ensure that 

comments on the information collection 

are received, OMB recommends that 

written comments be faxed to the Office 

of Information and Regulatory Affairs, 

OMB, Attn: DOJ Desk Officer, Fax: 202– 

395–7285, or be e-mailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number [1140–0078]. Also, 

include the DOJ docket number found 

in brackets in the heading of this 

document. If you have questions 

concerning the collection, please 

contact William Miller, 

William.Miller@atf.gov or the DOJ Desk 

Officer at 202–395–3176. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address one or more 

of the following four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection: 

Extension of a currently approved 

collection. 

(2) Title of the Form/Collection: 

Limited Permittee Transaction Record. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Justice sponsoring the 

collection: Form Number: None. Bureau 

of Alcohol, Tobacco, Firearms and 

Explosives. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Business or other forprofit. Other: Individuals or households. 

Abstract: The purpose of this collection 

is to ensure that records are available for 

tracing explosive materials when 

necessary and to ensure that limited 

permittees do not exceed their 

maximum allotment of receipts of 

explosive materials. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: There will be an estimated 

5,000 respondents, who will spend 

approximately 5 minutes to receive, file, 

and forward the appropriate 

documentation. 

(6) An estimate of the total burden (in 

hours) associated with the collection: 

There are an estimated 12,000 total 

burden hours associated with this 

collection. 

If additional information is required 

contact: Lynn Murray, Department 

Clearance Officer, United States 

Department of Justice, Policy and 

Planning Staff, Justice Management 

Division, Two Constitution Square, 

Room 2E–502, 145 N Street, NE., 

Washington, DC 20530. 

Dated: February 16, 2011. 

Lynn Murray, 

Department Clearance Officer, PRA, United 

States Department of Justice. 

[FR Doc. 2011–3952 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–FY–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Industrial 

Macromolecular Crystallography 

Association 

Correction 

In notice document 2011—2412 

appearing on page 6497 in the issue of 

Friday, February 4, 2011, make the 

following corrections: 

1. On page 6497, in the second 

column, in the document’s subject, 

‘‘Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Industrial Nacromolecular 

Crystallography Association’’ should 

read ‘‘Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Industrial Macromolecular 

Crystallography Association’’. 

2. On the same page, in the second 

column, in the fourth line from the 

bottom, ‘‘Industrial Nacromolecular’’ 

should read ‘‘Industrial 

Macromolecular.’’ 

3. On the same page, in the second 

column, in the third line from the 

bottom, ‘‘(‘‘INCA’’)’’ should read 

‘‘(‘‘IMCA’’)’’. 

4. On the same page, in the third 

column, in the fifth line of the second 

paragraph, ‘‘INCA’’ should read ‘‘IMCA’’. 

5. On the same page, in the third 

column, in the first line of the third 

paragraph, ‘‘INCA’’ should read ‘‘IMCA’’. 

[FR Doc. C1–2011–2412 Filed 2–22–11; 8:45 am] 

BILLING CODE 1505–01–D 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on January 

4, 2011, Sigma Aldrich Manufacturing 

LLC., 3500 Dekalb Street, St. Louis, 

Missouri 63118, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the following basic 

classes of controlled substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

Aminorex (1585) ........................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) ................... I 

Alpha-ethyltryptamine (7249) ....... I 

Ibogaine (7260) ............................ I 

Lysergic acid diethylamide (7315) I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (MDMA) (7405).

I 

4-Methoxyamphetamine (7411) ... I 

Bufotenine (7433) ......................... I 

mstockstill on DSKH9S0YB1PROD with NOTICES

10068 Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices 

Drug Schedule 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

N-Benzylpiperazine (BZP) (7493) I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Etonitazene (9624) ....................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Nabilone (7379) ............................ II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Opium, powdered (9639) ............. II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than [insert date 30 days 

from date of publication]. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3945 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69461, 

Wildlife Laboratories, 1401 Duff Drive, 

Suite 400, Fort Collins, Colorado 80524, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Etorphine Hydrochloride (9059), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance for sale to its 

customer. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and § 952(a) 

and determined that the registration of 

Wildlife Laboratories to import the basic 

class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Wildlife Laboratories to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3948 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on January 6, 2011, 

Johnson Matthey Pharmaceutical 

Materials Inc., Pharmaceutical Service, 

25 Patton Road, Devens, Massachusetts 

01434, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than April 25, 2011. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3928 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

mstockstill on DSKH9S0YB1PROD with NOTICES